FATE
HealthcareFate Therapeutics, Inc.
$1.15-0.01 (-0.72%)
Prev Close
$1.16
Open
$1.18
High
$1.19
Low
$1.14
Volume
784.1K
Market Cap
$156.4M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Fate Therapeutics, Inc. (FATE) has been exclusively selling, with 0 insider purchases totaling $0.00 and 6 insider sales totaling $58.6K. The most recent insider transaction was by TAHL CINDY (officer: See Remarks), who sold $11.3K worth of shares on Jan 12, 2026. Fate Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $156.4M.
Buys (12M)
0
$0.00
Sells (12M)
6
$58.6K
Net Activity
Net Seller
$58.6K
Active Insiders
2
last 12 mo
FATE Price Chart
FATE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026↗ | TAHL CINDY | officer: See Remarks | Sell | 10,589 | $1.06 | $11.3K | 387,081 |
| Jan 12, 2026↗ | Valamehr Bahram | director, officer: President and CEO | Sell | 5,190 | $1.07 | $5.6K | 329,708 |
| Jan 9, 2026↗ | TAHL CINDY | See Remarks | Sell | 10,589 | $1.06 | $11.3K | 0 |
| Jan 9, 2026↗ | Valamehr Bahram | President and CEO | Sell | 5,190 | $1.07 | $5.6K | 0 |
| Aug 4, 2025↗ | TAHL CINDY | See Remarks | Sell | 9,037 | $1.06 | $9.6K | 0 |
| Aug 4, 2025↗ | Valamehr Bahram | President and CEO | Sell | 14,466 | $1.06 | $15.4K | 0 |
| Jan 13, 2025↗ | Bressi Jerome Charles | See Remarks | Sell | 5,980 | $1.55 | $9.3K | 270,203 |
| Jan 13, 2025↗ | TAHL CINDY | See Remarks | Sell | 5,654 | $1.55 | $8.8K | 336,707 |
| Jan 13, 2025↗ | Valamehr Bahram | President and CEO | Sell | 8,705 | $1.54 | $13.4K | 349,364 |
| Dec 26, 2024↗ | Redmile Group, LLC | Director | Buy | 397,964 | $1.68 | $668.6K | 12,884,300 |
| Dec 26, 2024↗ | Redmile Group, LLC | Director | Sell | 341,633 | $1.68 | $573.9K | 12,486,300 |
| Aug 7, 2024↗ | Xu Yuan | Sell | 633 | $4.23 | $2.7K | 8,669 | |
| Mar 5, 2024↗ | Dulac Edward J III | Chief Financial Officer | Sell | 2,447 | $7.77 | $19.0K | 101,479 |
| Jan 30, 2024↗ | Dulac Edward J III | Chief Financial Officer | Sell | 1,849 | $5.00 | $9.2K | 103,926 |
| Jan 10, 2024↗ | Dulac Edward J III | Chief Financial Officer | Sell | 7,028 | $4.37 | $30.7K | 105,775 |
| Jan 10, 2024↗ | TAHL CINDY | General Counsel and Secretary | Sell | 10,874 | $4.37 | $47.5K | 142,361 |
| Jan 10, 2024↗ | Valamehr Bahram | Chief R&D Officer | Sell | 11,271 | $4.38 | $49.4K | 158,069 |
| Jan 10, 2024↗ | Wolchko J Scott | President and CEO | Sell | 14,391 | $4.37 | $62.9K | 371,248 |
| Jan 3, 2024↗ | Dulac Edward J III | Chief Financial Officer | Sell | 5,182 | $3.66 | $19.0K | 112,803 |
| Dec 28, 2023↗ | Redmile Group, LLC | Director | Buy | 44,630 | $3.72 | $166.0K | 13,180,400 |
| Dec 19, 2023↗ | Dulac Edward J III | Chief Financial Officer | Sell | 1,585 | $3.50 | $5.5K | 117,985 |
| Nov 13, 2023↗ | TAHL CINDY | General Counsel and Secretary | Sell | 24,363 | $2.40 | $58.5K | 153,235 |
| Aug 21, 2023↗ | Dulac Edward J III | Chief Financial Officer | Sell | 4,718 | $2.80 | $13.2K | 119,570 |
| Aug 7, 2023↗ | Xu Yuan | Director | Sell | 632 | $3.71 | $2.3K | 9,302 |
| Jul 6, 2023↗ | Dulac Edward J III | Chief Financial Officer | Sell | 5,182 | $4.83 | $25.0K | 124,288 |
| Jul 6, 2023↗ | Powl Brian T. | Chief Commercial Officer | Sell | 3,854 | $4.87 | $18.8K | 41,146 |
| Jun 15, 2023↗ | Xu Yuan | Director | Sell | 3,460 | $5.58 | $19.3K | 9,934 |
| Apr 21, 2023↗ | Redmile Group, LLC | Director | Buy | 276,639 | $6.17 | $1.71M | 13,135,800 |
| Apr 19, 2023↗ | Chu Yu-Waye | Chief Medical Officer | Sell | 2,532 | $6.57 | $16.6K | 142,993 |
| Apr 17, 2023↗ | Redmile Group, LLC | Director | Buy | 25,700 | $6.00 | $154.2K | 12,859,100 |
| Apr 17, 2023↗ | Redmile Group, LLC | Director | Sell | 302,339 | $5.84 | $1.77M | 12,833,400 |
| Jan 13, 2023↗ | MENDLEIN JOHN | Director | Buy | 124,679 | $5.60 | $698.1K | 282,770 |
| Jan 11, 2023↗ | Chu Yu-Waye | Chief Medical Officer | Sell | 7,825 | $5.24 | $41.0K | 143,208 |
| Jan 11, 2023↗ | Dulac Edward J III | Chief Financial Officer | Sell | 7,331 | $5.24 | $38.4K | 129,470 |
| Jan 11, 2023↗ | Plavsic Mark | Chief Technical Officer | Sell | 3,418 | $5.24 | $17.9K | 123,705 |
| Jan 11, 2023↗ | TAHL CINDY | General Counsel and Secretary | Sell | 11,553 | $5.24 | $60.5K | 177,598 |
| Jan 11, 2023↗ | Valamehr Bahram | Chief R&D Officer | Sell | 10,917 | $5.24 | $57.2K | 168,917 |
| Jan 11, 2023↗ | Wolchko J Scott | President and CEO | Sell | 45,907 | $5.24 | $240.6K | 385,639 |
| Aug 19, 2022↗ | Dulac Edward J III | Chief Financial Officer | Sell | 5,135 | $29.81 | $153.1K | 137,233 |
| Jul 25, 2022↗ | Wolchko J Scott | President and CEO | Sell | 36,246 | $32.74 | $1.19M | 450,717 |
| Jul 8, 2022↗ | Valamehr Bahram | Chief R&D Officer | Sell | 17,158 | $30.23 | $518.7K | 179,834 |
| Jul 7, 2022↗ | Valamehr Bahram | Chief R&D Officer | Sell | 7,842 | $30.07 | $235.8K | 179,834 |
| Jul 6, 2022↗ | Plavsic Mark | Chief Technical Officer | Sell | 3,719 | $24.61 | $91.5K | 127,123 |
| Jun 8, 2022↗ | Agarwal Shefali | Director | Sell | 841 | $21.89 | $18.4K | 1,840 |
| Jun 6, 2022↗ | Agarwal Shefali | Director | Sell | 807 | $22.80 | $18.4K | 1,874 |
| Jun 6, 2022↗ | COUGHLIN TIMOTHY | Director | Sell | 1,439 | $22.81 | $32.8K | 57,632 |
| Jun 6, 2022↗ | HERSHBERG ROBERT | Director | Sell | 672 | $22.75 | $15.3K | 2,009 |
| Jun 6, 2022↗ | Jooss Karin | Director | Sell | 1,483 | $22.82 | $33.8K | 1,198 |
| Jun 6, 2022↗ | MENDLEIN JOHN | Director | Sell | 1,364 | $22.79 | $31.1K | 158,091 |
| Jun 2, 2022↗ | TAHL CINDY | General Counsel and Secretary | Sell | 25,000 | $22.96 | $574.0K | 189,151 |
Showing 1–50 of 84
1 / 2
FATE Insider Buying Activity
The following table shows recent insider purchases of Fate Therapeutics, Inc. (FATE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 26, 2024↗ | Redmile Group, LLC | Director | Buy | 397,964 | $1.68 | $668.6K | 12,884,300 |
| Dec 28, 2023↗ | Redmile Group, LLC | Director | Buy | 44,630 | $3.72 | $166.0K | 13,180,400 |
| Apr 21, 2023↗ | Redmile Group, LLC | Director | Buy | 276,639 | $6.17 | $1.71M | 13,135,800 |
| Apr 17, 2023↗ | Redmile Group, LLC | Director | Buy | 25,700 | $6.00 | $154.2K | 12,859,100 |
| Jan 13, 2023↗ | MENDLEIN JOHN | Director | Buy | 124,679 | $5.60 | $698.1K | 282,770 |
FATE Insider Selling Activity
The following table shows recent insider sales of Fate Therapeutics, Inc. (FATE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026↗ | TAHL CINDY | officer: See Remarks | Sell | 10,589 | $1.06 | $11.3K | 387,081 |
| Jan 12, 2026↗ | Valamehr Bahram | director, officer: President and CEO | Sell | 5,190 | $1.07 | $5.6K | 329,708 |
| Jan 9, 2026↗ | TAHL CINDY | See Remarks | Sell | 10,589 | $1.06 | $11.3K | 0 |
| Jan 9, 2026↗ | Valamehr Bahram | President and CEO | Sell | 5,190 | $1.07 | $5.6K | 0 |
| Aug 4, 2025↗ | TAHL CINDY | See Remarks | Sell | 9,037 | $1.06 | $9.6K | 0 |
| Aug 4, 2025↗ | Valamehr Bahram | President and CEO | Sell | 14,466 | $1.06 | $15.4K | 0 |
| Jan 13, 2025↗ | Bressi Jerome Charles | See Remarks | Sell | 5,980 | $1.55 | $9.3K | 270,203 |
| Jan 13, 2025↗ | TAHL CINDY | See Remarks | Sell | 5,654 | $1.55 | $8.8K | 336,707 |
| Jan 13, 2025↗ | Valamehr Bahram | President and CEO | Sell | 8,705 | $1.54 | $13.4K | 349,364 |
| Dec 26, 2024↗ | Redmile Group, LLC | Director | Sell | 341,633 | $1.68 | $573.9K | 12,486,300 |
| Aug 7, 2024↗ | Xu Yuan | Sell | 633 | $4.23 | $2.7K | 8,669 | |
| Mar 5, 2024↗ | Dulac Edward J III | Chief Financial Officer | Sell | 2,447 | $7.77 | $19.0K | 101,479 |
| Jan 30, 2024↗ | Dulac Edward J III | Chief Financial Officer | Sell | 1,849 | $5.00 | $9.2K | 103,926 |
| Jan 10, 2024↗ | Dulac Edward J III | Chief Financial Officer | Sell | 7,028 | $4.37 | $30.7K | 105,775 |
| Jan 10, 2024↗ | TAHL CINDY | General Counsel and Secretary | Sell | 10,874 | $4.37 | $47.5K | 142,361 |
| Jan 10, 2024↗ | Valamehr Bahram | Chief R&D Officer | Sell | 11,271 | $4.38 | $49.4K | 158,069 |
| Jan 10, 2024↗ | Wolchko J Scott | President and CEO | Sell | 14,391 | $4.37 | $62.9K | 371,248 |
| Jan 3, 2024↗ | Dulac Edward J III | Chief Financial Officer | Sell | 5,182 | $3.66 | $19.0K | 112,803 |
| Dec 19, 2023↗ | Dulac Edward J III | Chief Financial Officer | Sell | 1,585 | $3.50 | $5.5K | 117,985 |
| Nov 13, 2023↗ | TAHL CINDY | General Counsel and Secretary | Sell | 24,363 | $2.40 | $58.5K | 153,235 |
| Aug 21, 2023↗ | Dulac Edward J III | Chief Financial Officer | Sell | 4,718 | $2.80 | $13.2K | 119,570 |
| Aug 7, 2023↗ | Xu Yuan | Director | Sell | 632 | $3.71 | $2.3K | 9,302 |
| Jul 6, 2023↗ | Dulac Edward J III | Chief Financial Officer | Sell | 5,182 | $4.83 | $25.0K | 124,288 |
| Jul 6, 2023↗ | Powl Brian T. | Chief Commercial Officer | Sell | 3,854 | $4.87 | $18.8K | 41,146 |
| Jun 15, 2023↗ | Xu Yuan | Director | Sell | 3,460 | $5.58 | $19.3K | 9,934 |
| Apr 19, 2023↗ | Chu Yu-Waye | Chief Medical Officer | Sell | 2,532 | $6.57 | $16.6K | 142,993 |
| Apr 17, 2023↗ | Redmile Group, LLC | Director | Sell | 302,339 | $5.84 | $1.77M | 12,833,400 |
| Jan 11, 2023↗ | Chu Yu-Waye | Chief Medical Officer | Sell | 7,825 | $5.24 | $41.0K | 143,208 |
| Jan 11, 2023↗ | Dulac Edward J III | Chief Financial Officer | Sell | 7,331 | $5.24 | $38.4K | 129,470 |
| Jan 11, 2023↗ | Plavsic Mark | Chief Technical Officer | Sell | 3,418 | $5.24 | $17.9K | 123,705 |
| Jan 11, 2023↗ | TAHL CINDY | General Counsel and Secretary | Sell | 11,553 | $5.24 | $60.5K | 177,598 |
| Jan 11, 2023↗ | Valamehr Bahram | Chief R&D Officer | Sell | 10,917 | $5.24 | $57.2K | 168,917 |
| Jan 11, 2023↗ | Wolchko J Scott | President and CEO | Sell | 45,907 | $5.24 | $240.6K | 385,639 |
| Aug 19, 2022↗ | Dulac Edward J III | Chief Financial Officer | Sell | 5,135 | $29.81 | $153.1K | 137,233 |
| Jul 25, 2022↗ | Wolchko J Scott | President and CEO | Sell | 36,246 | $32.74 | $1.19M | 450,717 |
| Jul 8, 2022↗ | Valamehr Bahram | Chief R&D Officer | Sell | 17,158 | $30.23 | $518.7K | 179,834 |
| Jul 7, 2022↗ | Valamehr Bahram | Chief R&D Officer | Sell | 7,842 | $30.07 | $235.8K | 179,834 |
| Jul 6, 2022↗ | Plavsic Mark | Chief Technical Officer | Sell | 3,719 | $24.61 | $91.5K | 127,123 |
| Jun 8, 2022↗ | Agarwal Shefali | Director | Sell | 841 | $21.89 | $18.4K | 1,840 |
| Jun 6, 2022↗ | Agarwal Shefali | Director | Sell | 807 | $22.80 | $18.4K | 1,874 |
| Jun 6, 2022↗ | COUGHLIN TIMOTHY | Director | Sell | 1,439 | $22.81 | $32.8K | 57,632 |
| Jun 6, 2022↗ | HERSHBERG ROBERT | Director | Sell | 672 | $22.75 | $15.3K | 2,009 |
| Jun 6, 2022↗ | Jooss Karin | Director | Sell | 1,483 | $22.82 | $33.8K | 1,198 |
| Jun 6, 2022↗ | MENDLEIN JOHN | Director | Sell | 1,364 | $22.79 | $31.1K | 158,091 |
| Jun 2, 2022↗ | TAHL CINDY | General Counsel and Secretary | Sell | 25,000 | $22.96 | $574.0K | 189,151 |
FATE Insiders
Similar Stocks to FATE
VRTX
Vertex Pharmaceuticals Incorporated
$466.13-0.02%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$758.67+0.23%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$325.50+2.03%
$42.07B
INSM
Insmed Incorporated
$145.13+0.35%
$30.07B
UTHR
United Therapeutics Corporation
$537.04+0.51%
$23.50B
MRNA
Moderna, Inc.
$55.67+4.52%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.20-0.21%
$20.08B
RPRX
Royalty Pharma plc
$46.17+0.17%
$19.56B